** Shares of telehealth firm Hims & Hers HIMS.N fall 6.2% to $37.98 premarket
** Novo Nordisk NOVOb.CO says it would offer doses of its weight-loss drug Wegovy at a reduced cost of $499 per month for cash paying customers in the United States
** Wegovy has a list price of around $1,350 a month, regardless of dosage
** Discounted drugs will be distributed through a program called NovoCare Pharmacy to uninsured patients or those whose insurance does not cover obesity medicines
** HIMS has benefited from selling cheaper copies, or compounded versions, of Wegovy
** Telehealth firm's shares have nearly tripled in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。